Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 36, Issue 1, 2009, Pages 39-62

  Zandvliet, Anthe S ^a   Schellens, Jan H M ^b,c   Copalu, William ^d   Beijnen, Jos H ^a,b   Huitema, Alwin D R ^a  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^d EISAI CO LTD   (Japan)

Author keywords

Clinical oncology; Dose individualization; Indisulam; NONMEM; Pharmacogenetics; Population pharmacokinetics and pharmacodynamics

Indexed keywords

CAPECITABINE; CYTOCHROME P450 2C; INDISULAM;

ARTICLE; BIOCHEMISTRY; BODY SURFACE; BONE MARROW SUPPRESSION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG INHIBITION; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPHIL; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; THROMBOCYTE COUNT; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTINEOPLASTIC AGENTS; BODY SURFACE AREA; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; CONTINENTAL POPULATION GROUPS; CYTOCHROME P-450 ENZYME SYSTEM; CYTOTOXINS; FEMALE; HEMATOLOGIC DISEASES; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MODELS, STATISTICAL; NEUTROPENIA; RISK; RISK FACTORS; SEX FACTORS; SULFONAMIDES; THROMBOCYTOPENIA; YOUNG ADULT;

EID: 61449100309     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-009-9111-2     Document Type: Article

References (32)

1. E Raymond WW ten Bokkel Huinink J Taieb JH Beijnen S Faivre J Wanders M Ravic P Fumoleau JP Armand JHM Schellens 2002 Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer J Clin Oncol 20 16 3508 3521 10.1200/JCO.2002.09.030
2. PN Mainwaring E Van Cutsem JL Van Laethem D Propper C Twelves J Bridgewater B Audhuy J Carmichael CJA Punt J Cassidy N Stuart M Ravic 2002 A multicentre randomised phase II study of E7070 in patients with colorectal cancer who have failed 5-fluorouracil-based chemotherapy Proc Am Soc Clin Oncol 21 153a Abstract
3. DC Talbot J von Pawel E Cattell SM Yule C Johnston AS Zandvliet ADR Huitema CJ Norbury P Ellis L Bosquee M Reck 2007 A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer Clin Cancer Res 13 6 1816 1822 10.1158/1078-0432.CCR-06-0249
4. RI Haddad LJ Weinstein TJ Wieczorek N Bhattacharya H Raftopoulos MW Oster X Zhang VM Latham Jr R Costello JL Faucher C DeRosa SM Yule LP Miller M Loda MR Posner GI Shapiro 2004 A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor Clin Cancer Res 10 14 4680 4687 10.1158/1078-0432.CCR-04-0229
5. Fumoleau P, Viens P, Cottu PH, De Grève J, Marty M, Delaloge S, Miles D, O'Reilly S, Wardley A, Schmid P, Ravic M, Paternoster M (2003) A multi center phase II study of E7070, a chloroindolyl-sulfonamide anticancer agent in anthracycline and taxane pre treated breast cancer. 26th San Antonio breast cancer symposium (abstract)
6. JF Smyth S Aamdal A Awada C Dittrich F Caponigro P Schoffski M Gore T Lesimple N Djurasinovic B Baron M Ravic P Fumoleau CJ Punt 2005 Phase II study of E7070 in patients with metastatic melanoma Ann Oncol 16 1 158 161 10.1093/annonc/mdi016
7. Raftopoulos H, Escudier B, Renshaw G, Lara PN, Dutcher J, Nanus D, Petrylak DP, Sacris L (2004) A phase II multicenter study of the cyclin-dependent kinase inhibitor indisulam in patients with inoperable and/or metastatic renal cell carcinoma (RCC). J Clin Oncol-ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22(14S):414s (abstract)
8. Cancer Therapy Evaluation Program: Common Toxicity Criteria, Version 2.0, DCTD, NCI, NIH, DHHS (1998)
9. C van Kesteren AS Zandvliet MO Karlsson RAA Mathôt CJA Punt JP Armand E Raymond ADR Huitema C Dittrich H Dumez H Roche JP Droz M Ravic SM Yule J Wanders JH Beijnen P Fumoleau JHM Schellens 2005 Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam Invest New Drugs 23 3 225 234 10.1007/s10637-005-6730-3
10. C van Kesteren RAA Mathôt E Raymond JP Armand C Dittrich H Dumez H Roche JP Droz CJA Punt M Ravic J Wanders JH Beijnen P Fumoleau JHM Schellens 2002 Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation J Clin Oncol 20 19 4065 4073 10.1200/JCO.2002.01.005
11. AS Zandvliet ADR Huitema W Copalu Y Yamada T Tamura JH Beijnen JHM Schellens 2007 CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity Clin Cancer Res 13 10 2970 2976 10.1158/1078-0432.CCR-06-2978
12. C Kloft J Wallin A Henningsson E Chatelut MO Karlsson 2006 Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs Clin Cancer Res 12 18 5481 5490 10.1158/1078-0432.CCR-06-0815
13. Y Yamada N Yamamoto T Shimoyama A Horiike Y Fujisaka K Takayama T Sakamoto Y Nishioka S Yasuda T Tamura 2005 Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days Cancer Sci 96 10 721 728 10.1111/j.1349-7006.2005.00109.x
14. Beal SL, Boeckman AJ, Sheiner LB (1988) NONMEM user's guides. University of California at San Francisco, San Francisco CA
15. L Zhang SL Beal LB Sheiner 2003 Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance J Pharmacokinet Pharmacodyn 30 6 387 404 10.1023/B:JOPA.0000012998.04442.1f
16. AS Zandvliet JHM Schellens W Copalu JH Beijnen ADR Huitema 2006 A semi-physiological population pharmacokinetic model describing the non-linear disposition of indisulam J Pharmacokinet Pharmacodyn 33 5 543 570 10.1007/s10928-006-9021-5
17. RJ Baker DD Kozoll KA Meyer 1957 The use of surface area as a basis for establishing normal blood volume Surg Gynecol Obstet 104 2 183 189
18. R Kawai D Mathew C Tanaka M Rowland 1998 Physiologically based pharmacokinetics of cyclosporine A: extension to tissue distribution kinetics in rats and scale-up to human J Pharmacol Exp Ther 287 2 457 468
19. AS Zandvliet WS Siegel-Lakhai JH Beijnen W Copalu MC Etienne-Grimaldi G Milano JH Schellens AD Huitema 2008 PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression Clin Pharmacol Ther 83 6 829 839 10.1038/sj.clpt.6100344
20. S Sadray EN Jonsson MO Karlsson 1999 Likelihood-based diagnostics for influential individuals in non-linear mixed effects model selection Pharm Res 16 8 1260 1265 10.1023/A:1014857832337
21. GB West JH Brown BJ Enquist 1997 A general model for the origin of allometric scaling laws in biology Science 276 5309 122 126 10.1126/science.276. 5309.122
22. JA Pieper MG Wyman BN Goldreyer DS Cannon RL Slaughter D Lalka 1980 Lidocaine toxicity: effects of total versus free lidocaine concentrations Circulation 62 Suppl.III 181
23. DG McDevitt M Frisk-Holmberg JW Hollifield DG Shand 1976 Plasma binding and the affinity of propranolol for a beta receptor in man Clin Pharmacol Ther 20 2 152 157
24. LE Friberg A Henningsson H Maas L Nguyen MO Karlsson 2002 Model of chemotherapy-induced myelosuppression with parameter consistency across drugs J Clin Oncol 20 24 4713 4721 10.1200/JCO.2002.02.140
25. CJA Punt P Fumoleau B van de Walle MN Faber M Ravic M Campone 2001 Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG) Ann Oncol 12 9 1289 1293 10.1023/A:1012287111922
26. C Dittrich H Dumez H Calvert A Hanauske M Faber J Wanders SM Yule M Ravic P Fumoleau 2003 Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors Clin Cancer Res 9 14 5195 5204
27. C Terret S Zanetta H Roche JHM Schellens MN Faber J Wanders M Ravic JP Droz 2003 Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG) Eur J Cancer 39 8 1097 1104 10.1016/S0959-8049(03)00128-X
28. WS Siegel-Lakhai AS Zandvliet AD Huitema MM Tibben G Milano V Girre V Dieras A King E Richmond J Wanders JH Beijnen JH Schellens 2008 A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours Br J Cancer 98 8 1320 1326 10.1038/sj.bjc.6604300
29. C Dittrich AS Zandvliet M Gneist ADR Huitema AA King J Wanders 2007 A phase I and pharmacokinetic study of indisulam in combination with carboplatin Br J Cancer 96 4 559 566 10.1038/sj.bjc.6603606
30. MM Oken RH Creech DC Tormey J Horton TE Davis ET McFadden PP Carbone 1982 Toxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 5 6 649 655 10.1097/00000421-198212000-00014
31. AS Zandvliet W Copalu JHM Schellens JH Beijnen ADR Huitema 2006 Saturable binding of indisulam to plasma proteins and distribution to human erythrocytes Drug Metab Dispos 34 6 1041 1046
32. Morgan GE, Mikhail MS, Murray MJ, Larson CP (2002) Clinical anesthesiology, 3rd edn. McGraw-Hill, Medical Publishing Division, New York